Bristol-Myers Squibb

AMRI Stock Tumbles After Announcing B-MS Trial Ends

AMRI Stock Tumbles After Announcing B-MS Trial Ends

By Zachary Brennan

Albany Molecular Research's (AMRI) stock fell more than 10% on Monday after announcing in an SEC filing that it was informed by its partner Bristol-Myers Squibb that it would terminate the development of an investigational depression drug.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers